Phenothiazines Boost Macrophage Antibacterial Activity via ROS and Autophagy

Study Background and Research Question

Bacterial infections remain a global health threat, responsible for millions of deaths annually, with antibiotic resistance posing an escalating challenge to public health. While conventional antibiotics primarily target bacterial components, the rise of drug-resistant pathogens and the persistence of intracellular bacteria—such as Salmonella enterica serovar Typhimurium and Shigella flexneri—have highlighted the limitations of this approach (Qiu et al., 2025). Host-directed therapies (HDTs) that enhance the host's innate immune response offer a promising alternative, circumventing the selection pressure for resistance and minimizing disruption to the microbiota. However, the precise mechanisms by which certain host-acting compounds (HACs), especially phenothiazine antipsychotics, modulate immune function and bacterial clearance have remained incompletely understood.

Key Innovation from the Reference Study

The study by Qiu et al. (2025) provides compelling evidence that phenothiazines, beyond their well-characterized effects as dopamine receptor antagonists, can amplify the antibacterial capacity of macrophages through two distinct cellular pathways: the induction of reactive oxygen species (ROS) and the activation of autophagy. The authors demonstrate that phenothiazine treatment leads to increased lysosomal activity, enhanced autophagic flux, and elevated ROS accumulation within macrophages, collectively contributing to improved elimination of intracellular pathogens (Qiu et al., 2025). Crucially, the antibacterial effects are abolished when either autophagy or ROS pathways are pharmacologically inhibited, underscoring the centrality of these mechanisms.

Methods and Experimental Design Insights

The research team employed a combination of in vitro and in vivo models to dissect the contributions of phenothiazines to macrophage-mediated bacterial clearance:

• Cellular models: Murine macrophage cultures were treated with phenothiazines, including perphenazine, and subsequently infected with representative intracellular pathogens (S. Typhimurium, S. flexneri, S. aureus, L. monocytogenes).
• Functional assays: The team quantified bacterial survival within macrophages and assessed cell viability to rule out nonspecific cytotoxic effects.
• Mechanistic interventions: Autophagy was inhibited pharmacologically (using agents such as bafilomycin A1), and ROS was scavenged with antioxidants, to test the necessity of these pathways for phenothiazine-mediated antibacterial activity.
• In vivo experiments: The efficacy of perphenazine in reducing organ lesions and inflammation was evaluated in a mouse model of S. Typhimurium infection.
• Molecular readouts: Lysosomal activity, autophagic flux (LC3-II/I ratio), and ROS levels were quantified using fluorescence-based assays and Western blotting.

The design ensured that observed effects could be directly attributed to phenothiazine modulation of host cell pathways rather than direct bactericidal action.

Core Findings and Why They Matter

The major findings from the study are as follows:

• Enhanced Intracellular Bacterial Clearance: Phenothiazine-treated macrophages exhibited significantly reduced intracellular bacterial burden, supporting a potentiation of innate immune functions.
• Autophagy and ROS as Essential Mediators: Pharmacological blockade of autophagy or ROS generation reversed the antibacterial effects, indicating that both processes are necessary for phenothiazine-induced protection (Qiu et al., 2025).
• Therapeutic Efficacy In Vivo: Infected mice treated with perphenazine, a phenothiazine compound, displayed reduced organ lesions and markers of inflammation.

These results are significant for several reasons. First, they demonstrate that phenothiazine compounds—historically developed as neuroleptics—can be repurposed as HDTs to enhance the host's own antimicrobial defenses, particularly in cases where conventional antibiotics are insufficient due to resistance or intracellular localization of pathogens. Second, by elucidating a dual mechanism involving both ROS and autophagy, the study offers a mechanistic foundation for rational design of combination therapies, potentially extending to other phenothiazine derivatives such as Chlorpromazine HCl.

Protocol Parameters

• cell-based antibacterial assay | 10–100 μM | macrophage infection models | Phenothiazine compounds enhance macrophage antibacterial activity within this concentration range without overt cytotoxicity | paper
• autophagy inhibition control | bafilomycin A1, 100 nM | mechanistic studies | Used to confirm autophagy dependence of phenothiazine response | paper
• ROS scavenger control | N-acetylcysteine, 1 mM | mechanistic studies | Used to confirm ROS dependence of phenothiazine response | paper
• Chlorpromazine HCl solubility | ≥71.4 mg/mL (water), ≥17.77 mg/mL (DMSO), ≥74.8 mg/mL (ethanol) | solution preparation | Ensures robust preparation for cell-based studies | product_spec
• Chlorpromazine HCl working concentration | 10–100 μM | mammalian cells | Standard range for dopamine receptor inhibition and autophagy modulation | workflow_recommendation

Comparison with Existing Internal Articles

Prior internal resources have focused primarily on the neuropharmacological roles of Chlorpromazine HCl, particularly its utility as a dopamine receptor antagonist in studies of psychotic disorders, GABAA receptor modulation, and endocytosis (AImmunity; Angiotensin-1-2-1-9). These articles elaborate on Chlorpromazine HCl’s well-characterized ability to block dopamine signaling and its emerging roles in neuroprotection and neurotransmission regulation. The current study extends beyond these domains, highlighting a novel immunomodulatory mechanism—induction of ROS and autophagy in macrophages—that is not addressed in the neuropharmacology-focused literature. This cross-domain insight broadens the scope of phenothiazine research, positioning these compounds as potential lead agents in infection biology as well as neuroscience.

Why this cross-domain matters, maturity, and limitations

The demonstration that phenothiazines can enhance host antibacterial defenses bridges neuropharmacology and immunology, suggesting that molecules initially developed for central nervous system targets may also serve in infection models. However, while the mechanisms of dopamine receptor antagonism and lysosomal modulation may intersect, the direct translation of neuropharmacological dosing to infection models requires further validation (BKM120). Additionally, although Chlorpromazine HCl shares the phenothiazine scaffold, its specific effects on macrophage antibacterial pathways should be independently confirmed, as subtle differences in pharmacodynamics may exist.

Limitations and Transferability

There are notable limitations to the study:

• Compound Specificity: While several phenothiazines were tested, most in vivo data centered on perphenazine. The extent to which Chlorpromazine HCl or other phenothiazines replicate these effects requires further work.
• Model Systems: The investigation employed murine macrophages and mouse infection models; transferability to human systems and clinical contexts remains to be established.
• Potential Off-target Effects: The broad pharmacology of phenothiazines raises the possibility of off-target actions not fully accounted for in this study.

Despite these limitations, the findings provide a strong rationale for further exploration of phenothiazines as HDTs in the context of antimicrobial resistance.

Research Support Resources

Researchers interested in reproducing or extending these workflows can access Chlorpromazine HCl (SKU B1480) from APExBIO, a phenothiazine dopamine receptor antagonist widely used in neuropharmacology, cell biology, and now increasingly in host-pathogen studies. Its established solubility profile and dosing range (10–100 μM) make it suitable for assays investigating dopamine receptor inhibition, autophagy modulation, and ROS-dependent mechanisms (product_spec). For detailed cell-based and infection model protocols, see referenced articles and product guidelines, ensuring adherence to recommended storage and solution stability parameters.